Querendia, a new drug for diabetes-related chronic kidney disease, has arrived in Spain

He Ministry of Health approved funding in Spain from Kerendia (Finerenone), new treatment Chronic kidney disease (CKD) Connected with type 2 diabetesmaking this drug now available to Spanish patients.

This new drug strengthens a therapeutic area with high patient and healthcare system burden and important unmet needs.

It is estimated that one in seven Spaniards have some degree Chronic kidney disease, namely 15.2% of the total; particularly significant impact among patients diabeticsas it is estimated that a third of people living with type 2 diabetes They end up developing some kind of kidney disease.

Expressed in years of life, a person with CKD And diabetes They live on average 16 years less than the general population. In addition, the initiation of renal replacement therapy, the most advanced stage of the disease, entails great emotional and psychological stress for the patient.

The consequences of this disease for the healthcare system are also very relevant, so the economic burden of CKD in patients with diabetes It increases sharply with deterioration of kidney function, mainly due to hospitalization of patients for cardiovascular reasons and dialysis.

In this sense, it is estimated that the annual cost per patient at the most advanced stage of the disease exceeds 16,000 euros.

Kerendia is a nonsteroidal, highly selective mineralocorticoid receptor (MR) antagonist that has been shown to block the deleterious effects of RM overactivation; hyperactivation, which contributes to the progression of CKD and damage to the cardiovascular system, which may be caused by metabolic, hemodynamic or inflammatory and fibrotic factors.

As noted Jose Luis Gorrishead of service nephrology belonging Clinical Hospital of the University of Valencia, “Finerenone may represent an important change in the prognosis of chronic kidney disease associated with type 2 diabetes. “This is a new therapeutic tool that has demonstrated renal and cardiovascular benefits in diabetic patients with good metabolic control and hypertension and helps reduce residual risk.”

In its turn, Alfonso Sotomedical assistant service Endocrinology belonging Hospital complex of the University of La Coruñanoted that “Integrated management of patients with CKD and T2DM is critical. To achieve this, we must act early on cardiovascular and renal failure using a multidisciplinary approach. Reducing cardiovascular events in these patients should be a priority as they are usually the leading cause of early mortality. Finerenone may become a key therapeutic agent for the treatment of cardiovascular diseases in our patients.“.

Except, “Family medicine should be encouraged to treat this patient early to prevent disease progression to later stages and greater cardiorenal risk.“He assured Ana Cebriandoctor by specialty Family and community medicine at the medical center Cartagena, Murcia Old Town.

In its turn, Guido Senatoremedical director Bayer in Spain explained regarding this new medicine that “We know the unmet needs of kidney patients, especially those living with diabetes. For this reason, we are proud to be able to provide you with therapies that will help manage your condition and especially reduce the residual risk you pose despite having already undergone treatment. Moreover, we are confident that Firenone will become the cornerstone of new treatments for the kidney and cardiovascular system, potentially improving the lives of even more patients in the future.“.